IE
CELZ icon

Israel Englander’s Creative Medical Technology CELZ Stock Holding History

Israel Englander’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,003
Closed -$4K – 6607
2022
Q3 		$4K Buy
+1,003
New +$6.8K ﹤0.01% 6837

Other funds holding CELZ

AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Israel Englander's CELZ Position: Q4 2022 in Review

Israel Englander sold out of Creative Medical Technology (CELZ) in Q4 2022, closing a stake of 1,003 shares — an estimated $4K sold.

Israel Englander first reported a position in CELZ in Q3 2022 and held it in 1 quarter. The position peaked at $4K in Q3 2022. 18 funds tracked by Wall St. Rank hold CELZ as of Q4 2022.

  • Israel Englander reported no remaining Creative Medical Technology position as of Q4 2022 after selling out during the quarter.
  • Israel Englander sold 1,003 Creative Medical Technology shares in Q4 2022, an estimated $4K.
  • Israel Englander first reported a position in Creative Medical Technology in Q3 2022 and held it in 1 quarter.
  • Israel Englander's Creative Medical Technology position peaked at $4K in Q3 2022.
  • 18 funds tracked by Wall St. Rank held Creative Medical Technology as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.